Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb

On December 16, 2022 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) reported that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) (Press release, Evotec, DEC 16, 2022, View Source [SID1234625352]). The collaboration expands the portfolio by two additional drug discovery projects and has designated a target-based programme for further development, triggering payments in total of US$ 26 m to Evotec.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for treatments that slow down or reverse disease progression. The collaboration leverages Evotec’s precision medicine technologies for modality-agnostic drug discovery and development. A first programme originating from the collaboration, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021, following the successful filing of an IND application with the FDA.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "We are delighted to see that after six years our neuroscience collaboration with Bristol Myers Squibb continues to be highly productive across its entire value chain. This is a testament to the scientific excellence and dedication of the teams at Evotec and Bristol Myers Squibb. We are confident that the growing pipeline of promising development candidates will yield transformative therapeutic options for patients living with neurodegenerative conditions."